No price history available for this symbol yet.
Held by
0
portfolios on TandT
Bookmarked by
0
users
Avg position size
—
of holders' portfolios
13F filers
0
institutions
Sector
Medical - Distribution
Shanghai Pharmaceuticals Holding Co., Ltd., an investment holding company based in Shanghai, People's Republic of China, maintains a robust presence across the pharmaceutical and healthcare industries. Its core activities involve the research, development, production, distribution, and retail of medical and wellness products. The company is strategically divided into Production, Distribution, Retail, and Other segments. Its comprehensive product portfolio includes Western and traditional Chinese medicines, health supplements, and medical devices, addressing a broad spectrum of therapeutic areas such as oncology, cardiovascular health, central nervous system disorders, general infections, immunology, digestive and metabolic conditions, and respiratory ailments, totaling approximately 700 distinct drug varieties. Beyond manufacturing, Shanghai Pharmaceuticals offers extensive pharmaceutical supply chain solutions, encompassing warehousing, logistics, and value-added services for manufacturers, hospitals, distributors, and retail pharmacies. The company also boasts a significant retail footprint, operating a network of approximately 2,000 retail pharmacies across 24 provinces, alongside an active online drug business. Furthermore, it provides various specialized services, including consulting, asset management, clinical trials, medical aid programs, physician and patient education, e-prescription management, and remote/cloud-based hospital services. Established in 1994, Shanghai Pharmaceuticals Holding Co., Ltd. operates as a subsidiary of Shanghai Pharmaceutical (Group) Co., Ltd.
www.sphchina.comNo one on the platform currently holds 2607.HK.
No tracked institution reports a position in 2607.HK as of their last filing.
No one on the platform has traded 2607.HK yet.
Consensus-seeded revenue, margins, and exit multiples. This is a scenario tool, not investment advice.
Consensus does not cover every selected forecast year. Later assumptions are extrapolated from available analyst estimates.
| Metric | Historical average | My assumptions | ||||
|---|---|---|---|---|---|---|
| 1 year | 5 years | 10 years | Low | Mid | High | |
| ROIC % | 7.2% | 7.8% | 9.0% | — | — | — |
| Rev. Growth % | 3.0% | 8.1% | ||||
| Profit Margin % | 2.0% | 2.0% | 2.2% | |||
| Free Cash Flow Margin % | 1.3% | 1.0% | 1.0% | |||
| Exit P/E | — | — | — | |||
| Exit P/FCF | — | — | — | |||
| Desired Annual Return % | — | — | — | |||
At today's price, your expected annual return is — on the P/E track.
At today's price, your expected annual return is — on the P/E track.
At today's price, your expected annual return is — on the P/E track.
No recent Form 4 filings on EDGAR — either no insider transactions reported recently or this isn't a SEC-registered issuer.
| Year | Est. revenue | Growth | Est. EPS | EPS range | Fwd P/E | # Analysts |
|---|---|---|---|---|---|---|
| 2026 | $299.7B | +5.1% | $1.50 | $1.45–$1.54 | — | 1 |
| 2027 | $316.2B | +5.5% | $1.56 | $1.50–$1.61 | — | 1 |
| 2028 | $337.4B | +6.7% | $1.67 | $1.61–$1.72 | — | 1 |
Forward consensus · growth is YoY vs the prior fiscal-year estimate · Fwd P/E at the current price · source: Financial Modeling Prep
Beat consensus in 3 of the last 8 reported quarters
| Reported | Est. EPS | Actual | Surprise |
|---|---|---|---|
| 2026-08-27 | $0.76 | $0.67 | -12.1% |
| 2026-04-29 | $0.40 | $0.43 | +7.6% |
| 2026-03-26 | $0.22 | $0.18 | -17.9% |
| 2025-10-30 | $0.31 | $0.21 | -32.1% |
| 2025-08-28 | $0.91 | $0.92 | +1.5% |
| 2025-04-24 | $0.45 | $0.38 | -14.3% |
| 2025-03-26 | $0.25 | $0.15 | -40.0% |
| 2024-10-29 | $0.27 | $0.30 | +11.1% |
| Symbol | Price | Today | Mkt cap | P/E |
|---|---|---|---|---|
| 2607.HKShanghai Pharmaceuticals Holding Co., Ltd | $11.01 | -1.17% | $63.9B | — |
| 0874.HKGuangzhou Baiyunshan Pharmaceutical Holdings Company Limited | $13.20 | -0.68% | $32.8B | — |
| 1099.HKSinopharm Group Co. Ltd. | $15.09 | -1.69% | $47.1B | — |
| 1530.HK3SBio Inc. | $16.03 | -1.17% | $40.1B | — |
| 2196.HKShanghai Fosun Pharmaceutical (Group) Co., Ltd. |
| $16.93 |
| -1.11% |
| $63.4B |
| — |
| 2228.HKXtalPi Holdings Ltd | $6.92 | +1.32% | $29.8B | — |
| 2268.HKWuXi XDC Cayman Inc | $75.15 | -0.86% | $95.2B | — |
Source: Financial Modeling Prep · peers by sector/industry